Evidence map›Paper›PMID 37847466›Full record

ArticleMolecular diversity2024

Synthesis and evaluation of imidazo[1,2-a]quinoxaline derivatives as potential antifungal agents against phytopathogenic fungi.

Taigui Ma, Xu Zhong, Ya Yang, Wenjing Liu, Bing Guo, Judi Fan, Lei Tang, Lingling Fan, Yong Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Synthesis and Biological Activity of Azolo[Molecules (Basel, Switzerland) · 2026
    Review
  2. Evaluation of innovative promising fungicide from nitropyrazolone class: effects on phytopathogens and non-target organisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Taigui MaGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Xu ZhongGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Ya YangGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Wenjing LiuGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Bing GuoGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Judi FanGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Lei TangGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Lingling FanGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China. fanling1025@126.com.
Yong LiGuizhou Provincial Key Laboratory of Pathogenesis and Drug Research On Common Chronic Diseases, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, People's Republic of China. liyong19851016@126.com.

Funding

Center for Biomedical Engineering Technology Acceleration (BETA Center)ZICEB000101 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI PLATT, MANU · 2023 to 2025
$2.3M
Special Research Project of Rural Economic Revitalization and Agricultural Industry Technology Project of Guizhou Medical University No. 26222190618The National Natural Science Foundation of China No.32060627 and No.22207021The State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering/Key Laboratory of Ministry of Education, Guizhou University No. 2021GDP0101, QianjiaoheKYzi[2022]362, and QianjiaoheKYzi[2020]250
6 · The paper itself

Abstract

To discover novel and effective potential agricultural antifungal agents, various kinds of imidazo[1,2-a]quinoxaline derivatives were designed, and synthesized from available and inexpensive reagents. Their antifungal activities were first evaluated against ten typical phytopathogenic fungi. The in vitro antifungal activity showed that some compounds exhibited more obvious broad-spectrum fungicidal activity than the two commercially-available fungicides chlorothalonil and hymexazol. Valsa mali and Botrytis cinerea strains exhibited the highest susceptibility with EC

Indexed as

Antifungal AgentsMicrobial Sensitivity TestsQuinoxalinesBotrytisFungiFungicides, IndustrialFusariumImidazolesPlant DiseasesStructure-Activity RelationshipAntifungal AgentsFungicides, IndustrialImidazolesQuinoxalinesAntifungal activityDesignimidazo[1,2-a]quinoxalineSynthesis

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.